Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-019-02014-5
Abstract: Impaired endogenous fibrinolysis is novel biomarker that can identify patients with ACS at increased cardiovascular risk. The addition of Very Low Dose Rivaroxaban (VLDR) to dual antiplatelet therapy has been shown to reduce cardiovascular events… read more here.
Keywords: status; vldr; low dose; addition ... See more keywords